Frank G. Schaap, Peter L.M. Jansen, Steven W.M. Olde Damink – 2 September 2017

Hidenori Toyoda, Kazuaki Chayama, Fumitaka Suzuki, Ken Sato, Tomofumi Atarashi, Tsunamasa Watanabe, Masanori Atsukawa, Atsushi Naganuma, Kazuo Notsumata, Yukio Osaki, Makoto Nakamuta, Koichi Takaguchi, Satoru Saito, Koji Kato, David Pugatch, Margaret Burroughs, Rebecca Redman, Katia Alves, Tami J. Pilot‐Matias, Rajneet K.

Muhammad Amir, Mark J. Czaja – 1 September 2017

Mohamed Bouattour, Eric Raymond, Shukui Qin, Ann‐Lii Cheng, Uz Stammberger, Giuseppe Locatelli, Sandrine Faivre – 1 September 2017 – Aberrant c‐Met activity has been implicated in the development of hepatocellular carcinoma (HCC), suggesting that c‐Met inhibition may have therapeutic potential. However, clinical trials of nonselective kinase inhibitors with c‐Met activity (tivantinib, cabozantinib, foretinib, and golvatinib) in patients with HCC have failed so far to demonstrate significant efficacy.

Mohamed Bouattour, Eric Raymond, Shukui Qin, Ann‐Lii Cheng, Uz Stammberger, Giuseppe Locatelli, Sandrine Faivre – 1 September 2017 – Aberrant c‐Met activity has been implicated in the development of hepatocellular carcinoma (HCC), suggesting that c‐Met inhibition may have therapeutic potential. However, clinical trials of nonselective kinase inhibitors with c‐Met activity (tivantinib, cabozantinib, foretinib, and golvatinib) in patients with HCC have failed so far to demonstrate significant efficacy.

Frailty is a critical determinant of outcomes in patients with cirrhosis. In this webinar we will present practical methods to assess and quantify frailty in both the outpatient and inpatient clinical settings. We will also provide recommendations on specific interventions once frailty is identified.Jody Olson (Moderator) Dr.

Laura Kulik, Julie K. Heimbach, Feras Zaiem, Jehad Almasri, Larry J Prokop, Zhen Wang, M. Hassan Murad, Khaled Mohammed – 31 August 2017 – Patients with hepatocellular carcinoma (HCC) who are listed for liver transplantation (LT) are often treated while on the waiting list with locoregional therapy (LRT), which is aimed at either preventing progression of HCC or reducing the measurable disease burden of HCC in order to receive increased allocation priority. We aimed to synthesize evidence regarding the effectiveness of LRT in the management of patients with HCC who were on the LT waitlist.

Bing‐liang Lin – 31 August 2017

Sheetal Trivedi, Satyapramod Murthy, Himanshu Sharma, Alex S. Hartlage, Arvind Kumar, Sashi V. Gadi, Peter Simmonds, Lokendra V. Chauhan, Troels K.H. Scheel, Eva Billerbeck, Peter D. Burbelo, Charles M. Rice, W. Ian Lipkin, Kurt Vandegrift, John M. Cullen, Amit Kapoor – 31 August 2017 – The lack of a relevant, tractable, and immunocompetent animal model for hepatitis C virus (HCV) has severely impeded investigations of viral persistence, immunity, and pathogenesis.

George V. Papatheodoridis, Spilios Manolakopoulos, Tung‐Hung Su, Spyros Siakavellas, Chun‐Jen Liu, Anastasia Kourikou, Hung‐Chih Yang, Jia‐Horng Kao – 31 August 2017 – Relapses are observed in most hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B patients who discontinue treatment with nucleos(t)ide analogues (NAs); however, the rates of relapse vary widely among studies, and whether all patients with relapse need retreatment is unclear.